ACE2 and COVID-19: Short tryptophan-containing peptides (EW in particular) have been demonstrated to reduce angiotensin-induced vasoconstriction and preserve endothelium-dependent vascular relaxation [13] by inhibiting ACE2, the target protein of SARS-CoV-2, which makes them promising candidates for investigation in the complex therapy of COVID-19 and post-COVID syndrome.